HALOZYME THERAPEUTICS INC (HALO:NASDAQ)
$107.06 -2.26 (-2.0673%)
Analysed HALOZYME THERAPEUTICS INC (HALO:NASDAQ) News Sources
2 Mid-Cap Stocks with Solid Fundamentals and 1 Facing Challenges
24-08-2026
yahoo.com
NeoGenomics, Inc. (NEO) Hits Fresh High: Is There Still Room to Run?
24-08-2026
yahoo.com
5 Biotech Stocks Worth Adding to Your Portfolio Now
26-08-2026
yahoo.com
Why Halozyme, An IBD 50 Stock, Just Hit A Record High In Bullish Volume
07-08-2026
yahoo.com
Halozyme Therapeutics Inc (HALO) (Q2 2026) Earnings Call Highlights: Record Revenue and Royalty ...
08-08-2026
yahoo.com
Halozyme Therapeutics (HALO) Is Up 24.9% After Raising 2026 Revenue Outlook and Boosting Buybacks
09-08-2026
yahoo.com
Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why
13-08-2026
yahoo.com
Halozyme (HALO) Q2 2026 Earnings Call Transcript
13-08-2026
fool.com
Incyte Corporation (INCY) has the Bigger Revenue Base, but Could Halozyme Therapeutics, Inc. (HALO) have the Better Economics?
14-08-2026
yahoo.com
The Top 5 Analyst Questions From Halozyme Therapeutics’s Q2 Earnings Call
15-08-2026
yahoo.com
What is the current price of HALOZYME THERAPEUTICS INC (HALO:NASDAQ)?
The current price of HALOZYME THERAPEUTICS INC (HALO:NASDAQ) is $107.06.
HALOZYME THERAPEUTICS INC (HALO:NASDAQ) absolute price change since previous trading day?
The absolute price change of HALOZYME THERAPEUTICS INC (HALO:NASDAQ) since the previous trading day is $-2.26.
HALOZYME THERAPEUTICS INC (HALO:NASDAQ) percentage price change since previous trading day?
The percentage price change of HALOZYME THERAPEUTICS INC (HALO:NASDAQ) since the previous trading day is -2.0673%.
What is the most recent average sentiment score for HALOZYME THERAPEUTICS INC (HALO:NASDAQ)?
The most recent average sentiment score for HALOZYME THERAPEUTICS INC (HALO:NASDAQ) is 80 out of 100.
What is the most recent average sentiment for HALOZYME THERAPEUTICS INC (HALO:NASDAQ)?
The most recent sentiment for HALOZYME THERAPEUTICS INC (HALO:NASDAQ) is .
SEC-8K** Filing Available For HALOZYME THERAPEUTICS INC (HALO:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.